Sign In
Buy CDNA
$22.31
+0.240 (+1.09%)
At Close: Jun 03, 2026
Why Cathie Wood Is Buying Beaten-Down CareDx
06:10am, Saturday, 06'th Nov 2021
Should you follow the internet's favorite stock picker into this tumbling diagnostics stock?
Why Are CareDx Shares Slumping Despite Q3 Earnings Beat?
12:03pm, Friday, 29'th Oct 2021
CareDx Inc (NASDAQ: CDNA) reported Q3 revenues rose 42% Y/Y to $75.6 million, beating the consensus of $74.05 million. The increase was driven mainly by a 46% increase in testing service revenues
Why CareDx Stock Is Falling Today Despite a Positive Earnings Call
11:53am, Friday, 29'th Oct 2021
Third-quarter 2021 results were terrific, but the disclosure of two federal investigations isn't sitting well with investors.
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2021 Results - Earnings Call Transcript
10:49pm, Thursday, 28'th Oct 2021
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2021 Results - Earnings Call Transcript
CareDx (CDNA) Q3 Earnings and Revenues Beat Estimates
06:20pm, Thursday, 28'th Oct 2021
CareDx (CDNA) delivered earnings and revenue surprises of 133.33% and 1.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CareDx to Report Third Quarter 2021 Financial Results
04:01pm, Thursday, 14'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinica
AlloSure, the First dd-cfDNA in Heart and Kidney Transplantation, Launches for Lung Transplant Patients
10:18am, Tuesday, 12'th Oct 2021
AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients
CareDx Extends Leadership in Multimodality Transplant Care with KidneyCare Validation Publication
04:01pm, Thursday, 30'th Sep 2021
Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with All
CareDx Continues to Fight for Innovation in Transplantation
07:18pm, Tuesday, 28'th Sep 2021
False Advertising Lawsuit Against Natera is Set to Go to Trial
CareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021
07:00am, Monday, 27'th Sep 2021
AlloSeq to be featured in 8 scientific abstracts at ASHI conference AlloSeq to be featured in 8 scientific abstracts at ASHI conference
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
04:37pm, Tuesday, 31'st Aug 2021
Which subset of the COVID-19 healthcare market will outperform over the next year?
CareDx Showcases Leadership in Global Transplantation at ESOT 2021
07:00am, Thursday, 26'th Aug 2021
CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium CareDx announces the launch of AlloSeq cfDNA Research Servic
CareDx: A Near-Term Capital-Gainer Among Healthcare Diagnostics, Say Market-Makers
09:03am, Sunday, 15'th Aug 2021
Why so reliant on M-Ms? Because they have the big-volume-trade clients who need their quick, quiet knowledgeable assistance while managing multi-billion-$ stock portfolios.
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2021 Results - Earnings Call Transcript
10:15am, Friday, 30'th Jul 2021
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2021 Results - Earnings Call Transcript
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
07:46pm, Thursday, 29'th Jul 2021
CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
